PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.37%
EBIT growth of 0.37% while Biotechnology median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
-2.64%
Negative operating income growth while Biotechnology median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
0.38%
Net income growth 50-75% of Biotechnology median of 0.65%. Guy Spier would worry about partial underperformance vs. peers.
3.04%
EPS growth below 50% of Biotechnology median of 6.67%. Jim Chanos would suspect fundamental earnings weakness or heavy dilution.
3.04%
Diluted EPS growth below 50% of Biotechnology median of 6.22%. Jim Chanos would suspect fundamental profit weaknesses or heavy share issuance.
2.54%
Share growth above Biotechnology median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
2.54%
Diluted share growth above 2x Biotechnology median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
10.47%
OCF growth of 10.47% while Biotechnology is zero. Walter Schloss might see a modest positive difference, which can compound over time.
10.65%
FCF growth of 10.65% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12900.29%
Negative 10Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-37006.68%
Negative 5Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-70.29%
Negative 3Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-15642.97%
Negative 10Y net income/share CAGR vs. Biotechnology median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
-43858.45%
Negative 5Y CAGR while Biotechnology median is 0.00%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-130.01%
Negative 3Y CAGR while Biotechnology median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
No Data
No Data available this quarter, please select a different quarter.
4179.35%
5Y equity/share CAGR of 4179.35% while Biotechnology median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
1066.60%
3Y equity/share CAGR of 1066.60% while Biotechnology median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.98%
Assets shrink while Biotechnology median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-27.26%
Negative BV/share change while Biotechnology median is -6.46%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-100.00%
Debt is shrinking while Biotechnology median is rising. Seth Klarman might see an advantage if growth remains possible.
37.07%
R&D growth of 37.07% while Biotechnology median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
-49.28%
SG&A decline while Biotechnology grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.